Shopping Cart
Remove All
Your shopping cart is currently empty
Ociperlimab (Synonyms: WCD-118, WCD118, BGB-A1217, BGBA1217)
Catalog No. T78324 Copy Product Info
🥰Excellent
Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors.
Ociperlimab
Copy Product Info🥰Excellent
Catalog No. T78324
Synonyms WCD-118, WCD118, BGB-A1217, BGBA1217
Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors.
Ociperlimab
Cas No. 2342597-93-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $742 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.17% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors. |
| Targets&IC50 | TIGIT:0.135 nM (Kd) |
| In vitro | Treatment with Ociperlimab (0-10 μg/mL) increased the secretion of IFN-γ by cytomegalovirus-specific T cells. Ociperlimab (1-1000 ng/mL) activates natural killer cells and monocytes in an FC-dependent manner. Ociperlimab removes TIGIT from the surface of T cells through FC-dependent endocytosis in vitro. [1] |
| In vivo | Ociperlimab (3 and 10 mg/kg; Intrabitoneal injection) in CT26 WT tumor-bearing human TIGIT knockout mice and MC38 tumor-bearing human TIGIT knockout mice showed that Ociperlimab produced anti-tumor effects in an FC-dependent manner. [1] |
| Synonyms | WCD-118, WCD118, BGB-A1217, BGBA1217 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TIGIT/VSIG9/VSTM3 |
| Molecular Weight | 145.12 kDa |
| Cas No. | 2342597-93-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Ociperlimab | purchase Ociperlimab | Ociperlimab cost | order Ociperlimab | Ociperlimab in vivo | Ociperlimab in vitro | Ociperlimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.